Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Locally Recurrent/Metastatic Triple Negative Breast Cancer”

46 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 46 results

Testing effectiveness (Phase 2)Study completedNCT02187991
What this trial is testing

Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer

Who this might be right for
Breast CancerBreast CarcinomaBreast Tumors+1 more
US Oncology Research 169
Testing effectiveness (Phase 2)WithdrawnNCT03644589
What this trial is testing

Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer

Who this might be right for
Estrogen Receptor NegativeHER2/Neu NegativeMetastatic Breast Cancer+3 more
University of Washington
Large-scale testing (Phase 3)Active Not RecruitingNCT05374512
What this trial is testing

Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

Who this might be right for
Breast Cancer
AstraZeneca 644
Testing effectiveness (Phase 2)Active Not RecruitingNCT03941730
What this trial is testing

Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Advanced Triple-Negative Breast CarcinomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+2 more
Mayo Clinic 8
Testing effectiveness (Phase 2)Study completedNCT00371254
What this trial is testing

Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer

Who this might be right for
Breast CancerMetastasis
Bristol-Myers Squibb 55
Testing effectiveness (Phase 2)Looking for participantsNCT06471205
What this trial is testing

BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer

Who this might be right for
Triple-negative Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 52
Large-scale testing (Phase 3)UnknownNCT00532727
What this trial is testing

Triple Negative Breast Cancer Trial

Who this might be right for
Breast Cancer
Institute of Cancer Research, United Kingdom 400
Testing effectiveness (Phase 2)Active Not RecruitingNCT02422498
What this trial is testing

Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy

Who this might be right for
Locally Recurrent/Metastatic Triple Negative Breast Cancer
Memorial Sloan Kettering Cancer Center 49
Not applicableActive Not RecruitingNCT07092254
What this trial is testing

Patterns of Care and Outcomes in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Daiichi Sankyo 760
Early research (Phase 1)Active Not RecruitingNCT04360941
What this trial is testing

PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast CancerLocally Advanced Breast CancerRecurrent Breast Cancer+3 more
Royal Marsden NHS Foundation Trust 45
Large-scale testing (Phase 3)Active Not RecruitingNCT06519370
What this trial is testing

FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 350
Testing effectiveness (Phase 2)Ended earlyNCT04191135
What this trial is testing

Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)

Who this might be right for
Triple Negative Breast Neoplasms
Merck Sharp & Dohme LLC 462
Early research (Phase 1)Study completedNCT01281150
What this trial is testing

Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Adult Solid NeoplasmEstrogen Receptor NegativeEstrogen Receptor Positive+8 more
National Cancer Institute (NCI) 22
Testing effectiveness (Phase 2)Looking for participantsNCT06682793
What this trial is testing

Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

Who this might be right for
Solid Tumor, AdultColorectal CancerNon-Small Cell Lung+14 more
A2 Biotherapeutics Inc. 240
Not applicableActive Not RecruitingNCT07018427
What this trial is testing

Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

Who this might be right for
Breast NeoplasmsTriple Negative Breast CancerHR+, HER2-, Advanced Breast Cancer+1 more
Peking University Cancer Hospital & Institute 70
Testing effectiveness (Phase 2)Looking for participantsNCT07208149
What this trial is testing

MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)

Who this might be right for
Triple-Negative Breast Cancer (TNBC)
Shenzhen Majory Biotechnology Co., Ltd. 42
Large-scale testing (Phase 3)Looking for participantsNCT07111832
What this trial is testing

A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

Who this might be right for
PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 400
Large-scale testing (Phase 3)Looking for participantsNCT06103864
What this trial is testing

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

Who this might be right for
Breast Cancer
AstraZeneca 625
Testing effectiveness (Phase 2)Active Not RecruitingNCT03616886
What this trial is testing

Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC

Who this might be right for
Triple Negative Breast Cancer
Jules Bordet Institute 129
Early research (Phase 1)Ended earlyNCT01876251
What this trial is testing

A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer

Who this might be right for
Breast Cancer Metastatic
Pfizer 30
Next Page